Calcitriol-mediated hypercalcemia as an immune-related adverse event in a patient receiving nivolumab and ipilimumab for metastatic renal cell carcinoma, case report.
Kai JohnsonMajd IssaAnish ParikhPaul MonkMing YinAmir MortazaviYuanquan YangPublished in: BMC urology (2021)
This case suggests calcitriol-mediated hypercalcemia as a novel immune-related adverse event.